KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Income from Continuing Operations: 2011-2024

Historic Income from Continuing Operations for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $235.0 million.

  • Sarepta Therapeutics' Income from Continuing Operations fell 7028.08% to -$447.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$248.7 million, marking a year-over-year decrease of 627.64%. This contributed to the annual value of $235.0 million for FY2024, which is 143.83% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Income from Continuing Operations stood at $235.0 million for FY2024, which was up 143.83% from -$536.1 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Income from Continuing Operations ranged from a high of $235.0 million in FY2024 and a low of -$704.1 million during FY2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$536.1 million (2023), whereas its average is -$335.1 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Income from Continuing Operations tumbled by 68.13% in 2022, and later skyrocketed by 143.83% in 2024.
  • Sarepta Therapeutics' Income from Continuing Operations (Yearly) stood at -$554.4 million in 2020, then increased by 24.46% to -$418.8 million in 2021, then crashed by 68.13% to -$704.1 million in 2022, then grew by 23.85% to -$536.1 million in 2023, then spiked by 143.83% to $235.0 million in 2024.